fashion -WSS

fashion

author：hotspot 2025-09-27 21:27:33 - browse：182

A new lawsuit accuses the health insurer Cigna of denying claims in bulk. Julia Rendleman/Getty Images for Eventive Marketing

A new lawsuit accuses Cigna of using an algorithm to automatically deny claims in bulk instead of individually reviewing each case, putting patients on the hook for bills the health insurer otherwise would have paid.

The complaint filed Monday in the Eastern District of California says Cigna uses a system called PXDX to identify discrepancies between diagnoses and the tests and services it covers for those ailments. The company then allegedly denies claims in bulk without looking into each coverage request. California law requires insurers to give each claim a “thorough, fair, and objective investigation.”

Once the claims are denied, the company allegedly has its physician reviewers sign off on batches of denials without opening each patient’s files to conduct detailed reviews. The complaint cites a March ProPublica article, which found that over a period of two months in 2022, Cigna doctors denied over 300,000 requests for payment using PXDX, spending an average of 1.2 seconds “reviewing” each request. One doctor alone denied 121,000 claims in that time period, according to the article.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： New chief aims to remake Sanofi Genzyme

knowledge

WSS

Pfizer's RSV vaccine recommended for approval in Europe

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

In same hospitals, Black patients receive fewer opioids than white patients

What to know about Virgin Galactic's 1st mission taking paying customers to space

How Brent Saunders' Allergan experiment failed

Emergent cuts jobs, executive role in business shake

hotspot

fashion

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

The cancer drug shortage isn’t new — and neither are the solutions

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Peter Hotez and the public health issue of online harassment

Why the advice to take all your antibiotics may be wrong

Walensky prepares to leave CDC — and Congress — behind

Hey, doctors: Don't be no

Apple is now the first public company to be valued at $3 trillion

Why Marc Tessier

focus

Trump Organization, Michael Cohen agree to settle million

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

The best solution to the drug shortages problem

A biotech analyst on neuroscience, placebo effect, not over

Pfizer's RSV vaccine recommended for approval in Europe

Wikipedia

Wikipedia

knowledge

explore